Zenas BioPharma (ZBIO)

Executive Summary

Zenas BioPharma is a clinical-stage biopharmaceutical company advancing innovative antibody and biologic therapies for autoimmune diseases. Its lead asset, obexelimab (a CD19/FcγRIIB dual-targeting antibody), is in Phase 3 for warm autoimmune hemolytic anemia (AIHA) with topline data expected in the second half of 2026, and in Phase 2 for systemic lupus erythematosus (SLE) and relapsing multiple sclerosis (RMS). The company also holds exclusive rights to orelabrutinib, a BTK inhibitor in Phase 3 for progressive forms of multiple sclerosis (PPMS and SPMS), with recruitment ongoing. Zenas employs an asset-centric strategy, focusing on late-stage programs with validated mechanisms to address high unmet needs. With a public listing (NASDAQ: ZBIO) and a market capitalization of approximately $1.2 billion, the company is poised for potential value inflection from upcoming clinical data readouts.

Upcoming Catalysts (preview)

• Q3 2026Obexelimab Phase 3 Top-Line Data in Warm AIHA65% success
• Q4 2026Obexelimab Phase 2 Top-Line Data in SLE45% success
• Q2 2026Obexelimab Phase 2 Data in Relapsing MS50% success